BRAF and melanoma: The proportion of this population can be increased by treatment with a BRAF inhibitor (BRAFi) or BRAFi plus a MEK inhibitor (MEKi), designed to target the common BRAF mutations in melanoma that activate MAPK signalling, suggesting this population plays a crucial role in drug resistance.